Skip to main content

Table 2 Summary of clinical features observed between severe Hb S/β+, Hb S/β0 and Hb SS groups

From: Sickle cell disease in Sri Lanka: clinical and molecular basis and the unanswered questions about disease severity

Clinical feature/Complication severe Hb S/β+
group
n = 37
Hb S/β0 group
n = 14
Hb SS group
n = 9
Cumulative Figure
N = 60
p value1 between two SBT groups p value2 between all three groups
Joint pain 20 (54.05%) 12 (85.70%) 7 (77.78%) 39 (65.0%) 0.053 0.080
Palpable spleen 26 (70.27%) 7 (50.0%) 3 (33.33%) 36 (60.0%) 0.204 0.086
Hospital admission due to pain 20 (54.05%) 10 (71.43%) 5 (55.56%) 35 (58.33%) 0.346 0.562
Jaundice 14 (37.84%) 9 (64.28%) 6 (66.67%) 29 (48.33%) 0.120 0.109
Major infections 13 (35.14%) 4 (28.57%) 4 (44.44%) 21 (35.0%) 0.749 0.744
Recurrent headaches 11 (29.73%) 1 (7.14%) 2 (22.22%) 14 (23.33%) 0.142 0.281
Pica 6 (16.22%) 3 (21.43%) 2 (22.22%) 11 (18.33%) 0.692 0.711
Abdominal pain 6 (16.22%) 4 (28.57%) 0 10 (16.67%) 0.432 0.217
Dactylitis 3 (8.11%) 3 (21.43%) 4 (44.44%) 10 (16.67%) 0.327 0.027*
Gallstones 6 (16.22%) 3 (21.43%) 1 (11.11%) 10 (16.67%) 0.692 0.888
Pallor 4 (10.81%) 2 (14.28%) 3 (33.33%) 9 (15.0%) 0.661 0.220
Acute chest syndrome 3 (8.11%) 3 (21.43%) 2 (22.22%) 8 (13.33%) 0.327 0.290
Vision impairment 8 (21.62%) 0 0 8 (13.33%) 0.088 0.074
Abdominal distension 3 (8.11%) 1 (7.14%) 1 (11.11%) 5 (8.33%) 1.000 1.000
Facial deformities 1 (2.70%) 2 (14.28%) 0 3 (5.0%) 0.179 0.189
Nocturnal enuresis 2 (5.40%) 1 (7.14%) 0 3 (5.0%) 1.000 1.000
Leg ulcers 2 (5.40%) 1 (7.14%) 0 3 (5.0%) 1.000 1.000
  1. 1Fisher’s exact test p < 0.05 was taken as significant between two SBT groups
  2. 2Fisher’s exact test p < 0.05 was taken as significant between all three groups